The Association Between Depressive Symptoms and Systemic Inflammation in People With Type 2 Diabetes: Findings From the South London Diabetes Study

OBJECTIVE The prevalence of depression and depressive symptoms is increased twofold in people with type 2 diabetes compared with the general population and is associated with worse biomedical outcomes and increased mortality. Type 2 diabetes, cardiovascular disease, and depression in nondiabetes subjects are independently associated with raised concentrations of circulating inflammatory markers, but it is not known if a similar association is observed in type 2 diabetes. We tested the hypothesis that higher depressive symptom scores in newly diagnosed type 2 diabetes patients were associated with higher concentrations of inflammatory markers. RESEARCH DESIGN AND METHODS Depressive symptoms in adults with newly diagnosed type 2 diabetes recruited from primary care were assessed using the Patient Health Questionnaire-9. Twelve markers of inflammation (C-reactive protein [hs-CRP], interleukin-4 [IL-4], IL-6, IL-10, vascular endothelial growth factor [VEGF], tumor necrosis factor-α [TNF-α], IL-1β, IL-1 receptor antagonist [IL-1RA], monocyte chemotactic protein-1 [MCP-1], white blood cell count [WBC], adiponectin, and triglyceride [TG]) were measured. Covariates included sociodemographic factors, adiposity, macrovascular disease, HbA1c, and prescribed medication. The association between each inflammatory marker and depressive symptom score was estimated by multiple linear regression. RESULTS The baseline cohort consisted of 1,790 participants. After adjusting for covariates, CRP (B = 0.13, P < 0.001), IL-1β (B = 0.06, P = 0.047), IL-1RA (B = 0.13, P < 0.001), MCP-1 (B = 0.11, P = 0.001), WBC (B = 0.13, P < 0.001), and TG (B = 0.10, P < 0.001) were associated with depressive symptoms. CONCLUSIONS Increased inflammation may be involved in the pathogenesis of depressive symptoms in type 2 diabetes and contribute to the increased risk of complications and mortality in this group.

[1]  T. Harris,et al.  Diabetes, depressive symptoms, and inflammation in older adults: results from the Health, Aging, and Body Composition Study. , 2013, Journal of psychosomatic research.

[2]  Karina Lovell,et al.  Patient Health Questionnaire , 2013 .

[3]  D. Ståhl,et al.  Comparison of Depressive Symptoms in Type 2 Diabetes Using a Two-Stage Survey Design , 2013, Psychosomatic medicine.

[4]  A. Beekman,et al.  Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression , 2013, Molecular Psychiatry.

[5]  K. Brady,et al.  Association of elevated cytokines with childhood adversity in a sample of healthy adults. , 2013, Journal of psychiatric research.

[6]  B. Penninx,et al.  Depressive symptoms and white blood cell count in coronary heart disease patients: Prospective findings from the Heart and Soul Study , 2013, Psychoneuroendocrinology.

[7]  S. Sivaprasad,et al.  The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D) , 2013, Diabetologia.

[8]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[9]  B. Antuna-Puente,et al.  Adiponectin: anti-inflammatory and cardioprotective effects. , 2012, Biochimie.

[10]  Do Peterson,et al.  Collaborative care for patients with depression and chronic illnesses. , 2010, The New England journal of medicine.

[11]  F. Pouwer,et al.  Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis , 2010, Diabetologia.

[12]  K. Ismail.  Unraveling the Pathogenesis of the Depression–Diabetes Link , 2010 .

[13]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[14]  R. Schwarzer,et al.  Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. , 2010, The Journal of clinical psychiatry.

[15]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[16]  F. Pouwer,et al.  Depression and Type 2 Diabetes Over the Lifespan: A Meta-Analysis , 2009, Diabetes Care.

[17]  J. Pickup,et al.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X , 1997, Diabetologia.

[18]  M. Roizen,et al.  Examining a Bidirectional Association Between Depressive Symptoms and Diabetes , 2009 .

[19]  M. H. Pollack,et al.  A detailed examination of cytokine abnormalities in Major Depressive Disorder , 2008, European Neuropsychopharmacology.

[20]  José Manuel Fernández-Real,et al.  Innate immunity, insulin resistance and type 2 diabetes , 2008, Trends in Endocrinology & Metabolism.

[21]  D. Ståhl,et al.  A Cohort Study of People With Diabetes and Their First Foot Ulcer , 2007, Diabetes Care.

[22]  G. Lorenzo,et al.  Decreased plasma adiponectin concentration in major depression , 2006, Neuroscience Letters.

[23]  Kohjiro Ueki,et al.  Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. , 2006, The Journal of clinical investigation.

[24]  A. Beekman,et al.  Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis , 2006, Diabetologia.

[25]  Evette Ludman,et al.  The association of comorbid depression with mortality in patients with type 2 diabetes. , 2005, Diabetes care.

[26]  J. Pickup.  Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. , 2004, Diabetes care.

[27]  J. Pickup,et al.  Activation of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellitus , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[28]  G. Nichols,et al.  Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. , 2003, Diabetes care.

[29]  C. Meisinger,et al.  C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. , 2003, Archives of internal medicine.

[30]  Nancy R Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.

[31]  W. Arend.  The balance between IL-1 and IL-1Ra in disease. , 2002, Cytokine & growth factor reviews.

[32]  C. Dowrick,et al.  Depressive disorders in Europe: prevalence figures from the ODIN study , 2001, British Journal of Psychiatry.

[33]  M. Rubenfire,et al.  Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. , 2001, The American journal of cardiology.

[34]  K. Freedland,et al.  Association of Depression and Diabetes Complications: A Meta-Analysis , 2001, Psychosomatic medicine.

[35]  K. Freedland,et al.  The prevalence of comorbid depression in adults with diabetes: a meta-analysis. , 2001, Diabetes care.

[36]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[37]  W. Katon,et al.  Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. , 2000, Archives of internal medicine.

[38]  R. Carney,et al.  Depression and poor glycemic control: a meta-analytic review of the literature. , 2000, Diabetes care.

[39]  R. Spitzer,et al.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. , 1999, JAMA.

[40]  A. Whitehead,et al.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.